Application of butylphthalide or derivatives thereof in preparing drug for treating or preventing brain paralysis

A technology of butylphthalide and derivatives, applied in the field of pharmaceutical use

Active Publication Date: 2016-04-06
SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the research on butylphthalide in the treatment of cerebral palsy has not been reported at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of butylphthalide or derivatives thereof in preparing drug for treating or preventing brain paralysis
  • Application of butylphthalide or derivatives thereof in preparing drug for treating or preventing brain paralysis
  • Application of butylphthalide or derivatives thereof in preparing drug for treating or preventing brain paralysis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Example 1 Preparation of an animal model of cerebral palsy.

[0077] 1. Animal model preparation:

[0078] 60 clean-grade mature female rats and 30 male rats, weighing 200-280g. Female rats and male rats were reared routinely at room temperature (25°C±5°C), free to eat and drink, with half and half light and dark cycles (12h / 12h), after two weeks of environmental adaptation, at 17:00 p.m. at 2:1 (female: Male) were kept together in the same cage, and the vaginal smear was checked at 8 o'clock in the morning of the next day, and the sperm found was regarded as the 0th day of pregnancy, and the pregnant mice were raised in another cage;

[0079] The pregnant rats were randomly divided into the control group (n=20) and the model group (n=22), and the pregnant rats in the model group on the 17th day of pregnancy were given lipopolysaccharide (serotype 0.55: B5 strain, Sigma company) 450 μg / kg, continuously Two days of intraperitoneal injection, the same dose of normal sa...

Embodiment 2

[0098] Embodiment 2: Butylphthalide pair Big Therapeutic or preventive effects of cerebral palsy in mice.

[0099] 1. Preparation of animals and models:

[0100] 1.1 Animal model preparation:

[0101]120 clean-grade mature female rats and 60 male rats, weighing 200-280g. Female rats and male rats were reared routinely at room temperature (25°C±5°C), free to eat and drink, with half and half light and dark cycles (12h / 12h), after two weeks of environmental adaptation, at 17:00 p.m. at 2:1 (female: Male) were kept together in the same cage, and the vaginal smear was checked at 8 o'clock in the morning of the next day, and the sperm found was regarded as the 0th day of pregnancy, and the pregnant mice were raised in another cage;

[0102] The pregnant rats were randomly divided into the control group (n=15) and the cerebral palsy group (n=90), and the pregnant rats in the model group on the 17th day of pregnancy were given lipopolysaccharide (serotype 0.55: B5 strain, Sigma...

Embodiment 3

[0133] Example 3: Therapeutic or preventive effects of butylphthalide derivatives on cerebral palsy in guinea pigs.

[0134] 1. Preparation of animals and models:

[0135] 1.1 Animal model preparation:

[0136] 100 clean-grade mature female rats and 50 male rats, weighing 200-280g. All the other are with embodiment 2;

[0137] Randomly select 20 pups from the control group and 100 pups from the cerebral palsy group (divided into 5 groups). The control group was fed routinely for 42 days. On the basis of routine feeding, the other groups were given different doses of butylphthalide derivatives, and neurological examination was carried out. Behavioral testing and motor function assessment.

[0138] 1.2 Grouping and administration:

[0139] (1) Normal control group: intragastric administration of the same volume of normal saline;

[0140] (2) Cerebral palsy model group: 20 cerebral palsy animal models were administered with the same amount of normal saline;

[0141] (3) 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides new application of butylphthalide, and relates to application of the butylphthalide or derivatives thereof in preparing a drug for treating or preventing brain paralysis.

Description

technical field [0001] The invention relates to the field of medicine application, in particular to the application of butylphthalide or its derivatives in the preparation of medicines for treating or preventing cerebral palsy. Background technique [0002] Pediatric cerebral palsy, also known as pediatric cerebral palsy, commonly known as cerebral palsy, refers to the syndrome caused by non-progressive brain damage and developmental defects from conception to infancy, mainly manifested as movement disorders and abnormal postures, which may be accompanied by varying degrees Mental retardation, convulsions, abnormal psychological behavior, sensory disturbance and other abnormalities. It is a syndrome with different clinical manifestations rather than a single disease. Cerebral palsy is a common central nervous system disorder syndrome in childhood. The lesion is located in the brain and involves the limbs. It is often accompanied by mental retardation, epilepsy, abnormal beh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K36/537A61K31/192A61P25/28A61P25/00A61K31/045
Inventor 牛锋齐军彩黄慭侯兴普韩春景
Owner SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap